- Home
- ETNB vs ENVX Comparison
ETNB vs ENVX Comparison
Compare ETNB & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- ENVX
- Stock Information
- Founded
- ETNB 2018
- ENVX 2006
- Country
- ETNB United States
- ENVX United States
- Employees
- ETNB N/A
- ENVX N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- ENVX Industrial Machinery/Components
- Sector
- ETNB Health Care
- ENVX Miscellaneous
- Exchange
- ETNB Nasdaq
- ENVX Nasdaq
- Market Cap
- ETNB 1.5B
- ENVX 1.5B
- IPO Year
- ETNB 2019
- ENVX N/A
- Fundamental
- Price
- ETNB $10.08
- ENVX $8.23
- Analyst Decision
- ETNB Strong Buy
- ENVX Strong Buy
- Analyst Count
- ETNB 8
- ENVX 11
- Target Price
- ETNB $26.43
- ENVX $18.27
- AVG Volume (30 Days)
- ETNB 2.2M
- ENVX 3.6M
- Earning Date
- ETNB 08-04-2025
- ENVX 07-30-2025
- Dividend Yield
- ETNB N/A
- ENVX N/A
- EPS Growth
- ETNB N/A
- ENVX N/A
- EPS
- ETNB N/A
- ENVX N/A
- Revenue
- ETNB N/A
- ENVX $22,900,000.00
- Revenue This Year
- ETNB N/A
- ENVX $55.18
- Revenue Next Year
- ETNB N/A
- ENVX $253.52
- P/E Ratio
- ETNB N/A
- ENVX N/A
- Revenue Growth
- ETNB N/A
- ENVX 77.59
- 52 Week Low
- ETNB $4.16
- ENVX $5.27
- 52 Week High
- ETNB $11.84
- ENVX $18.68
- Technical
- Relative Strength Index (RSI)
- ETNB 57.88
- ENVX 52.26
- Support Level
- ETNB $9.66
- ENVX $8.03
- Resistance Level
- ETNB $10.58
- ENVX $9.03
- Average True Range (ATR)
- ETNB 0.55
- ENVX 0.50
- MACD
- ETNB -0.09
- ENVX -0.04
- Stochastic Oscillator
- ETNB 58.39
- ENVX 50.60
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About ENVX Enovix Corporation
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.